Weight loss program aims to open door to kidney transplants for obese patients
NCT ID NCT06396416
First seen Feb 21, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This study tests whether a virtual weight management program, including a weight-loss drug called semaglutide, can help people with obesity and advanced kidney disease lose enough weight to become eligible for a kidney transplant. About 60 adults with a BMI over 35 and high risk of kidney failure will be randomly assigned to the program or usual care. The main goal is to see if such a study is feasible, not yet to prove the program works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
London Health Sciences Centre
RECRUITINGLondon, Ontario, N6A 5A5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.